We conducted a prospective randomized study in which patients with biopsy-confirmed idiopathic membranous nephropathy were assigned to receive either a six-month course of prednisone given on alternate days (45 mg per square meter of body-surface area; n = 81) or no specific treatment (n = 77). The mean duration of follow-up was 48 months. Patients in the prednisone group (median age, 46 years) entered with a mean disease duration of 15 months, a median creatinine clearance of 1.2 ml per second per 1.73 m2 (range, 0.25 to 2.6), and a median rate of urinary protein excretion of 6.8 g per day (0.3 to 26). The annual change in the corrected creatinine clearance at six months did not differ between the prednisone group and the control group (0.10 vs. 0.06 ml per second; P = 0.8), or at the last follow-up evaluation (-0.07 vs. -0.02 ml per second; P = 0.2; 95 percent confidence interval on the difference, -0.03 to 0.13). The proportion of patients with complete remission of proteinuria was also similar in the groups at 6 and 12 months and after a mean of 48 months. Outcomes were similar in the two groups with respect to progression to renal failure (3 vs. 4 patients), death (3 vs. 1 patient), complete remission of proteinuria at 36 months (16 vs. 19 patients), and a decline of 25 percent or more in the creatinine clearance at 60 months (32 vs. 25 percent of patients). A multivariate analysis, which adjusted for differences at entry in sex distribution, urinary protein excretion, and creatinine concentration, as well as other prognostic variables, failed to provide an explanation for the lack of effect of prednisone. We conclude that a six-month course of therapy in which prednisone is given on alternate days is of no benefit to patients with idiopathic membranous nephropathy.
Source Information
Department of Medicine, University of Toronto, ON, Canada.
This article has been cited by other articles:
Eriguchi, M., Oka, H., Mizobuchi, T., Kamimura, T., Sugawara, K., Harada, A.
(2009). Long-term outcomes of idiopathic membranous nephropathy in Japanese patients treated with low-dose cyclophosphamide and prednisolone. Nephrol Dial Transplant
24: 3082-3088
[Abstract][Full Text]
Austin, H. A. III, Illei, G. G., Braun, M. J., Balow, J. E.
(2009). Randomized, Controlled Trial of Prednisone, Cyclophosphamide, and Cyclosporine in Lupus Membranous Nephropathy. J. Am. Soc. Nephrol.
20: 901-911
[Abstract][Full Text]
Hofstra, J. M., Wetzels, J. F. M.
(2008). Introduction of a cyclophosphamide-based treatment strategy and the risk of ESRD in patients with idiopathic membranous nephropathy: A nationwide survey in the Netherlands. Nephrol Dial Transplant
23: 3534-3538
[Abstract][Full Text]
Fervenza, F. C., Sethi, S., Specks, U.
(2008). Idiopathic Membranous Nephropathy: Diagnosis and Treatment. CJASN
3: 905-919
[Abstract][Full Text]
Kinane, T. B., Grabowski, E. F., Sharma, A., Nimkin, K., King, M. E., Cornell, L. D.
(2008). Case 7-2008 -- A 17-Year-Old Girl with Chest Pain and Hemoptysis. NEJM
358: 941-952
[Full Text]
Glassock, R. J.
(2007). Prophylactic Anticoagulation in Nephrotic Syndrome: A Clinical Conundrum. J. Am. Soc. Nephrol.
18: 2221-2225
[Abstract][Full Text]
Jha, V., Ganguli, A., Saha, T. K., Kohli, H. S., Sud, K., Gupta, K. L., Joshi, K., Sakhuja, V.
(2007). A Randomized, Controlled Trial of Steroids and Cyclophosphamide in Adults with Nephrotic Syndrome Caused by Idiopathic Membranous Nephropathy. J. Am. Soc. Nephrol.
18: 1899-1904
[Abstract][Full Text]
Alexopoulos, E., Papagianni, A., Tsamelashvili, M., Leontsini, M., Memmos, D.
(2006). Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome. Nephrol Dial Transplant
21: 3127-3132
[Abstract][Full Text]
Cattran, D.
(2005). Management of Membranous Nephropathy: When and What for Treatment. J. Am. Soc. Nephrol.
16: 1188-1194
[Full Text]
du Buf-Vereijken, P.W.G., Feith, G.W., Hollander, D., Gerlag, P.G.G., Wirtz, J.J.J.M., Noordzij, T.C., Wetzels, J.F.M.
(2004). Restrictive use of immunosuppressive treatment in patients with idiopathic membranous nephropathy: high renal survival in a large patient cohort. QJM
97: 353-360
[Abstract][Full Text]
Kataoka, S., Kudo, A., Hirano, H., Kawakami, H., Kawano, T., Higashihara, E., Tanaka, H., Delarue, F., Sraer, J.-D., Mune, T., Krozowski, Z. S., Yan, K.
(2002). 11{beta}-Hydroxysteroid Dehydrogenase Type 2 Is Expressed in the Human Kidney Glomerulus. J. Clin. Endocrinol. Metab.
87: 877-882
[Abstract][Full Text]
Tang, S., Chan, T.M., Cheng, I.K.P., Lai, K.N.
(1999). Clinical features and treatment outcome of idiopathic membranous nephropathy in Chinese patients. QJM
92: 401-406
[Abstract][Full Text]
van Ypersele de Strihou, C.
(1994). Fish Oil for IgA Nephropathy?. NEJM
331: 1227-1229
[Full Text]
Schieppati, A., Mosconi, L., Perna, A., Mecca, G., Bertani, T., Garattini, S., Remuzzi, G.
(1993). Prognosis of Untreated Patients with Idiopathic Membranous Nephropathy. NEJM
329: 85-89
[Abstract][Full Text]
Austin, H. A. III, Antonovych, T. T., MacKay, K., Boumpas, D. T., Balow, J. E.
(1992). Membranous Nephropathy. ANN INTERN MED
116: 672-682
[Abstract]
Falk, R. J., Hogan, S. L., Muller, K. E., Jennette, J. C., Glomerular Disease Collaborative Network,
(1992). Treatment of Progressive Membranous Glomerulopathy: A Randomized Trial Comparing Cyclophosphamide and Corticosteroids with Corticosteroids Alone. ANN INTERN MED
116: 438-445
[Abstract]
Bruns, F. J., Adler, S., Fraley, D. S., Segel, D. P.
(1991). Sustained Remission of Membranous Glomerulonephritis after Cyclophosphamide and Prednisone. ANN INTERN MED
114: 725-730
[Abstract]
Previous
